Maxim Stetsyuk, CEO of NANOLEK, has clinched the Eurasian Pharma Award in the “Business Success” nomination.
This is a first time in history that a competition is held this year, in 2020, among the pharmaceutical manufacturers of the Eurasian Union. 72 nominees representing 13 different countries expressed their willingness to face the challenge, considering the fact that pharmaceutical markets of these nations are on the agenda of the Eurasian Virtual Pharmaceutical Summit (Russia, Kazakhstan, Uzbekistan, Azerbaijan, Kyrgyzstan, Belarus, Armenia, Ukraine, Georgia, Moldova, Turkmenistan, Tajikistan, Mongolia).
As stated by Natalya Bayeva, Director of the Eurasian Virtual Pharmaceutical Summit, most applications for the Eurasian Pharma Awards were filed by pharmaceutical companies to compete for “The Best Digital Project” nomination. It shows that the pharmaceutical sector witnesses a rapid development, especially amidst the challenges during the current year.
Maxim Stetsyuk: “I’m very obliged that you value so much my professional contribution, but this victory, though in the personal nomination, is primarily due to well-coordinated work of the whole team. The greatest strength of every company is people. That is why I express my gratitude to all employees of NANOLEK who we work with together to make the company grow and develop, to pursue our mission in unchanged way: to protect people’s lives and health by making the best world technologies available to everyone. Our success is a well-balance day-to-day interaction, sometimes by working at our limits. I’m sure that many victories lie ahead of us since we have an enormous potential.”
Maxim Stetsyuk has been working in the capacity of CEO at NANOLEK since 2018; in March 2020, he joined the board of Nanolek LLC. During his tenure with the company he managed to increase several times the sales, implement global structural changes by generating the company’s first profit and enabling export of drugs to the CIS countries.
By the end of the year 2019, the enterprise’s revenue increased by 60% and amounted to 7.5 billion rubles as compared to the 2018 metric. The company’s investment volume exceeded RUB M500. The profit was 596 million rubles. The company’s tax deductions to the budget of the Kirov region amounted to 100 million rubles.